Drugs / Trifluridine/tipiracil
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07280377 Background | Oct 2021 → Jul 2027 expected | anal squamous cell carcinoma, pancreatic ductal adenocarcinoma | Oncolytics Biotech | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | “Trifluridine/tipiracil administered at a 35 mg/m2 dose orally twice daily” NCT07280377 ↗ |
| Route | Oral | “administered at a 35 mg/m2 dose orally twice daily” NCT07280377 ↗ |